PMID- 31203104 OWN - NLM STAT- MEDLINE DCOM- 20200520 LR - 20200520 IS - 1873-5835 (Electronic) IS - 0145-2126 (Linking) VI - 83 DP - 2019 Aug TI - The upregulation of Pim kinases is essential in coordinating the survival, proliferation, and migration of KIT D816V-mutated neoplastic mast cells. PG - 106166 LID - S0145-2126(19)30112-2 [pii] LID - 10.1016/j.leukres.2019.106166 [doi] AB - About 80% of mast cell neoplasm patients harbor the c-Kit activating mutation D816 V, which is associated with c-Kit inhibitor resistance and poor prognosis. However, the molecular basis for these effects is not fully known. To address this issue, in this study we screened molecules whose expression is altered by KIT D816 V mutation and found that Pim kinases were overexpressed in D816V-mutant neoplastic mast cells. This was accompanied by upregulation of signal transducer and activator of transcription (STAT) and mammalian target of rapamycin (mTOR) and downregulation of Akt and extracellular signal-regulated kinase (ERK1/2). Activated Pim kinases promoted the survival of D816 V cells by maintaining mTOR and p70S6K activation even under nutrient starvation. Conversely, cell proliferation was suppressed by inhibiting Pim kinases. The mRNA level of C-X-C chemokine receptor type 4 (CXCR4) was about 2-fold higher in D816 V cells; this was associated with a 2-fold increase in migratory capacity, which was modulated by Pim kinases. We also confirmed that upregulation of Pim kinases is a feature specific to cells with the D816 V mutation and is not observed in cells with the c-Kit activating N822 K mutation. These data suggest Pim kinases as a promising therapeutic target for the treatment of mast cell neoplasms with KIT D816 V mutation. CI - Copyright (c) 2019. Published by Elsevier Ltd. FAU - Park, Hyejoo AU - Park H AD - Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea. FAU - Kim, Dongchan AU - Kim D AD - Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea. FAU - Koh, Youngil AU - Koh Y AD - Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea. FAU - Yoon, Sung-Soo AU - Yoon SS AD - Cancer Research Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea; Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea. Electronic address: ssysmc@snu.ac.kr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190612 PL - England TA - Leuk Res JT - Leukemia research JID - 7706787 RN - EC 2.7.10.1 (KIT protein, human) RN - EC 2.7.10.1 (Proto-Oncogene Proteins c-kit) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-pim-1) RN - EC 2.7.11.1 (proto-oncogene proteins pim) SB - IM MH - Amino Acid Substitution MH - Cell Line, Tumor MH - *Cell Movement MH - *Cell Proliferation MH - Cell Survival MH - *Gene Expression Regulation, Enzymologic MH - *Gene Expression Regulation, Leukemic MH - Humans MH - Leukemia, Mast-Cell/*enzymology/genetics/pathology MH - *MAP Kinase Signaling System MH - *Mutation, Missense MH - Proto-Oncogene Proteins c-kit/*biosynthesis/genetics MH - Proto-Oncogene Proteins c-pim-1/*biosynthesis/genetics MH - *Up-Regulation OTO - NOTNLM OT - Cell migration OT - Cell survival OT - KITD816V OT - Mast cell neoplasm OT - Pim kinase EDAT- 2019/06/17 06:00 MHDA- 2020/05/21 06:00 CRDT- 2019/06/17 06:00 PHST- 2019/03/29 00:00 [received] PHST- 2019/05/19 00:00 [revised] PHST- 2019/06/06 00:00 [accepted] PHST- 2019/06/17 06:00 [pubmed] PHST- 2020/05/21 06:00 [medline] PHST- 2019/06/17 06:00 [entrez] AID - S0145-2126(19)30112-2 [pii] AID - 10.1016/j.leukres.2019.106166 [doi] PST - ppublish SO - Leuk Res. 2019 Aug;83:106166. doi: 10.1016/j.leukres.2019.106166. Epub 2019 Jun 12.